Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers
Author: Kenny, L.
Broadhurst, D.
Dunn, W.
Brown, M.
North, R.
McCowan, L.
Roberts, C.
Cooper, G.
Kell, D.
Baker, P.
Citation: Hypertension, 2010; 56(4):741-749
Publisher: Lippincott Williams & Wilkins
Issue Date: 2010
ISSN: 0194-911X
Statement of
Louise C. Kenny, David I. Broadhurst, Warwick Dunn, Marie Brown, Robyn A. North, Lesley McCowan, Claire Roberts, Garth J.S. Cooper, Douglas B. Kell, Philip N. Baker, on behalf of the Screening for Pregnancy Endpoints Consortium
Abstract: Preeclampsia is a pregnancy-specific syndrome that causes substantial maternal and fetal morbidity and mortality. The etiology is incompletely understood, and there is no clinically useful screening test. Current metabolomic technologies have allowed the establishment of metabolic signatures of preeclampsia in early pregnancy. Here, a 2-phase discovery/validation metabolic profiling study was performed. In the discovery phase, a nested case-control study was designed, using samples obtained at 15±1 weeks’ gestation from 60 women who subsequently developed preeclampsia and 60 controls taking part in the prospective Screening for Pregnancy Endpoints cohort study. Controls were proportionally population matched for age, ethnicity, and body mass index at booking. Plasma samples were analyzed using ultra performance liquid chromatography-mass spectrometry. A multivariate predictive model combining 14 metabolites gave an odds ratio for developing preeclampsia of 36 (95% CI: 12 to 108), with an area under the receiver operator characteristic curve of 0.94. These findings were then validated using an independent case-control study on plasma obtained at 15±1 weeks from 39 women who subsequently developed preeclampsia and 40 similarly matched controls from a participating center in a different country. The same 14 metabolites produced an odds ratio of 23 (95% CI: 7 to 73) with an area under receiver operator characteristic curve of 0.92. The finding of a consistent discriminatory metabolite signature in early pregnancy plasma preceding the onset of preeclampsia offers insight into disease pathogenesis and offers the tantalizing promise of a robust presymptomatic screening test.
Keywords: preeclampsia
Rights: © 2010 American Heart Association, Inc.
DOI: 10.1161/HYPERTENSIONAHA.110.157297
Published version:
Appears in Collections:Aurora harvest
Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.